Dan Becker

Dan Becker is currently Director at Perfuse Therapeutics, Inc. since 2020, Independent Director at Zura Bio Ltd. starting 2025, Director at Areteia Therapeutics, Inc. since 2024, Managing Director at Access Biotechnology (Venture Capital) since 2019, Director at DOT Therapeutics-2, Inc., Director at Hemab ApS since 2023, Director at Matchpoint Therapeutics, Inc. since 2021, and Principal at Access Industries LLC since 2019.
Former roles include Independent Director at Day One Biopharmaceuticals, Inc. from 2019 to 2024, Independent Director at ACELYRIN, Inc. from 2022 to 2025, Independent Director at Principia Biopharma, Inc. from 2017 to 2020, Director at DTx Pharma, Inc. from 2021 to 2023, Director at Mariana Oncology, Inc. from 2021 to 2024, Independent Non-Executive Director at Pandion Therapeutics, Inc. from 2020 to 2021, Principal at The Boston Consulting Group, Inc. from 2009 to 2015, and Principal at New Leaf Venture Partners LLC from 2015 to 2019.
Education includes a doctorate from the University of Michigan, graduate and doctorate degrees from the University of Michigan Medical School, and an undergraduate degree from the University of Illinois At Urbana–Champaign.